Guanidine → HCID 20729541、化合物

反応式

[F:1][C:2]1[CH:3]=[C:4]([CH:18]=[CH:19][C:20]=1[F:21])[CH2:5][NH:6][C:7]([C:9]1[NH:10][CH:11]=[C:12]([C:14](=O)[CH2:15][CH3:16])[CH:13]=1)=[O:8].[CH:22](OC(C)(C)C)(N(C)C)N(C)C.[NH2:34][C:35]([NH2:37])=[NH:36]>C1COCC1>[F:1][C:2]1[CH:3]=[C:4]([CH:18]=[CH:19][C:20]=1[F:21])[CH2:5][NH:6][C:7]([C:9]1[NH:10][CH:11]=[C:12]([C:14]2[C:15]([CH3:22])=[CH:16][N:34]=[C:35]([NH2:37])[N:36]=2)[CH:13]=1)=[O:8]

参加物

実験手順

To a solution of compound 6 (1 equivalent) in THF, at ambient temperature, was added (Me2N)2CHOt-Bu (3 equivalents). After 24 hours, the solvent was evaporated and the crude product was utilized without purification. Step 2: To a solution of the compound formed above at Step 1 (1 equivalent) in ethanol, at ambient temperature, was added guanidine (3 equivalents) and the resulting mixture heated at reflux. After 12 hours, the solvent was evaporated and the crude product purified by preparatory HPLC (reverse phase; 10–90% MeCN in water; 15 minutes) to afford the desired compound III-a-74. HPLC using method B provided Rt of 7.9 minutes. 1H NMR was consistent with expected structure. FIA/MS Obs. M+1/M−1.